重大新闻！Waymo 召回 672 辆自动驾驶汽车，引发自动驾驶安全担忧

Waymo 召回 672 辆自动驾驶汽车，引发自动驾驶安全担忧

北京，2024年6月14日 - 据报道，Alphabet 旗下自动驾驶公司 Waymo 正在召回 672 辆自动驾驶汽车，原因是这些车辆存在软件故障，可能导致转向系统失灵。

此次召回涉及 Waymo 的 L4 级自动驾驶汽车，包括 Waymo One 和 Waymo Waymo One robotaxi。 这些车辆配备了激光雷达、摄像头和其他传感器，能够在没有人类驾驶员的情况下自主行驶。

Waymo 表示，此次召回是由于软件缺陷导致转向系统在某些情况下可能无法正常工作。 具体来说，在车辆处于低速状态并准备转弯时，转向系统可能会出现延迟或失效。

Waymo 已经开始联系受影响的车辆车主，并安排免费维修。 车主将需要将车辆送往 Waymo 的服务中心进行软件更新。

此次召回事件引发了人们对自动驾驶安全性的担忧。 一些专家指出，自动驾驶汽车的软件系统非常复杂，即使是微小的缺陷也可能导致严重后果。

Waymo 是全球领先的自动驾驶公司之一。 该公司一直在努力开发和测试自动驾驶技术，以期将其推向商业应用。

此次召回事件对 Waymo 的发展可能产生负面影响。 投资者可能会对自动驾驶技术的安全性产生疑虑，Waymo 的商业化进程也可能会受到阻碍。

以下是一些关于此次召回事件的细节：

• 受影响的车辆数量：672 辆
• 受影响的车辆型号：Waymo One 和 Waymo Waymo One robotaxi
• 召回原因：软件缺陷导致转向系统可能失灵
• 召回措施：免费维修软件

请注意：

• 本文仅供参考，不构成任何投资建议。
• 本文中的信息可能存在误差或遗漏，恕不承担任何责任。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.